Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 652

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

Open access
Nemes, Elisa, Geldenhuys, Hennie, Rozot, Virginie, Rutkowski, Kathryn T., Ratangee, Frances, Bilek, Nicole, Mabwe, Simbarashe, Makhethe, Lebohang, Erasmus, Mzwandile, Toefy, Asma, Mulenga, Humphrey, Hanekom, Willem A., Self, Steven G., Bekker, Linda-Gail, Ryall, Robert, Gurunathan, Sanjay, DiazGranados, Carlos A., Andersen, Peter, Kromann, Ingrid, Evans, Thomas, Ellis, Ruth D., Landry, Bernard, Hokey, David A., Hopkins, Robert, Ginsberg, Ann M., Scriba, Thomas J., Hatherill, Mark·2018·New England Journal of Medicine

Abstract

BACKGROUND: Recent Mycobacterium tuberculosis infection confers a predisposition to the development of tuberculosis disease, the leading killer among global infectious diseases. H4:IC31, a candidate subunit vaccine, has shown protection against tuberculosis disease in preclinical models, and observational studies have indicated that primary bacille Calmette-Guérin (BCG) vaccination may offer partial protection against infection. METHODS: In this phase 2 trial, we randomly assigned 990 adolescents in a high-risk setting who had undergone neonatal BCG vaccination to receive the H4:IC31 vaccine, BCG revaccination, or placebo. All the participants had negative results on testing for M. tuberculosis infection on the QuantiFERON-TB Gold In-tube assay (QFT) and for the human immunodeficiency virus. The primary outcomes were safety and acquisition of M. tuberculosis infection, as defined by initial conversion on QFT that was performed every 6 months during a 2-year period. Secondary outcomes were immunogenicity and sustained QFT conversion to a positive test without reversion to negative status at 3 months and 6 months after conversion. Estimates of vaccine efficacy are based on hazard ratios from Cox regression models and compare each vaccine with placebo. RESULTS: Both the BCG and H4:IC31 vaccines were immunogenic. QFT conversion occurred in 44 of 308 participants (14.3%) in the H4:IC31 group and in 41 of 312 participants (13.1%) in the BCG group, as compared with 49 of 310 participants (15.8%) in the placebo group; the rate of sustained conversion was 8.1% in the H4:IC31 group and 6.7% in the BCG group, as compared with 11.6% in the placebo group. Neither the H4:IC31 vaccine nor the BCG vaccine prevented initial QFT conversion, with efficacy point estimates of 9.4% (P=0.63) and 20.1% (P=0.29), respectively. However, the BCG vaccine reduced the rate of sustained QFT conversion, with an efficacy of 45.4% (P=0.03); the efficacy of the H4:IC31 vaccine was 30.5% (P=0.16). There were no clinically significant between-group differences in the rates of serious adverse events, although mild-to-moderate injection-site reactions were more common with BCG revaccination. CONCLUSIONS: In this trial, the rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high-transmission setting. This finding may inform clinical development of new vaccine candidates. (Funded by Aeras and others; C-040-404 ClinicalTrials.gov number, NCT02075203 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1714021

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 652

Metadata

Authors
Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., Mulenga, H., Hanekom, W. A., Self, S. G., Bekker, L.-G., Ryall, R., Gurunathan, S., DiazGranados, C. A., Andersen, P., Kromann, I., Evans, T., Ellis, R. D., Landry, B., Hokey, D. A., Hopkins, R., Ginsberg, A. M., Scriba, T. J., & Hatherill, M.
Venue
New England Journal of Medicine
Published
2018-07-12
Volume
379
Issue
2
Pages
138-149
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2872754763
Cited by
652
References
32
FWCI
56.54
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. https://app.cochat.ai/papers/10.1056/nejmoa1714021
The paper
Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N., Mabwe, S., Makhethe, L., Erasmus, M., Toefy, A., Mulenga, H., Hanekom, W. A., Self, S. G., Bekker, L.-G., Ryall, R., Gurunathan, S., DiazGranados, C. A., Andersen, P., Kromann, I., . . . Hatherill, M. (2018). Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1714021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.